Healthcare Leaders Hub

🏠Home 📰News 📝Blog 🎬Videos Advertise Login

Your trusted source for pharmaceutical news, expert insights, and healthcare innovation.

💼𝕏 👥▶️

Content

📰News
📝Blog
🎬Videos

Company

🏠Home
🏢About Us
📧Contact

© 2026 PharmaVoice. All rights reserved. Empowering healthcare leaders.

Privacy Policy•Terms of Service

Pharma Tech

Peptide innovator says the drug class is due for a rethink

Sep 2, 2026, 11:05 AM

Read Full Article → Peptide innovator says the drug class is due for a rethink

Peptide innovator says the drug class is due for a rethink

Translate article text

Choose a language and wait for the translated text.

Karsten Eastman, CEO of Sethera Therapeutics, discusses developments in peptides from cutting-edge innovation to mass consumption.

Peptide innovator says the drug class is due for a rethink | PharmaVoice